Skip to main content

a2a/a2b adenosine receptor antagonist incb106385

Generic: A2A/A2B Adenosine Receptor Antagonist INCB106385

a2a/a2b adenosine receptor antagonist incb106385: 2 clinical trials tracked.

a2a/a2b adenosine receptor antagonist incb106385 evidence translation

What we can confirm

2 tracked trials

No verified listed company relationship

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about a2a/a2b adenosine receptor antagonist incb106385, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence7 indications · 1 study sponsors
Clinical Trial Registry Records (2)

A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors

NCT04989387Registry updated 2025-09-02·Phase 1·INCY
Terminated

Primary endpoint: Evaluation of the safety and tolerability of INCA00186 as monotherapy and in combination with retifanlimab and/or INCB106385 as measured by the number of participants with adverse eventsductions and withdrawal of treatment due to AEs

Interventionalopen57 targetStarted 2021-10Completion 2024-0932 sites · Austria, Belgium, Netherlands, Spain…Incyte Corporation

A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors

NCT04580485Registry updated 2025-07-11·Phase 1·INCY
Completed

Primary endpoint: Number of treatment-emergent adverse events (TEAE)

Interventionalopen54 enrolledStarted 2021-02Completion 2024-0127 sites · Belgium, France, Italy, Spain…Incyte Corporation